– USA, IL – Accretive Health, Inc. (OTC Pink: ACHI) today announced that its Board of Directors has appointed Emad Rizk, M.D., president of McKesson Health Solutions, as Chief Executive Officer, President, and a member of the Board of Directors, effective July 21, 2014.
In its search for a new CEO, the Board sought a candidate with leadership experience, a passion for operational excellence, a proven track record for growth and deep healthcare domain expertise to lead the company through its next phase of operational enhancement, and to reignite the company’s growth and strategic innovation.
“The Board was very strategic about finding the right person to become our new CEO – Emad is that person,” said Steve Shulman, chairman of Accretive Health’s Board of Directors. “He is a renowned healthcare industry expert who brings with him more than 25 years of experience, and at the same time has demonstrated a profound ability to drive growth and innovation.”
Since 2003, Dr. Rizk has served as president of McKesson Health Solutions, a division of McKesson Corporation. As president of this division, he built a world-class team and oversaw significant growth, with a focus on helping providers and payers implement new delivery and financial payment processes as the healthcare industry transitions from volume- to value-based care. During his tenure, he built an organization that became a leader in the healthcare industry.
Prior to joining McKesson, Dr. Rizk served as senior partner and global director of Deloitte Consulting, prior to which he was worldwide medical director for Monsanto Corporation. He also currently serves on the board of Accuray Incorporated. In 2013, Dr. Rizk was named one of the 50 Most Influential Physician Executives in the United States by Modern Physician, the fifth time he has been recognized by this publication. He has also been counted among the Top 100 Most Powerful People in Healthcare by Modern Healthcare; and named one of the nation’s Top 25 Leaders in Disease Management by Managed Healthcare Executive.
“I am very honored by the trust the Accretive Health Board of Directors has placed in me, and excited about the opportunities and potential of Accretive Health,” said Dr. Rizk. “I have spent the better part of my career identifying, assessing, developing and achieving significant strategic potential in the healthcare ecosystem. Accretive Health represents that kind of potential to me.”
“Accretive Health has the right fundamentals, the right vision, the right talent and the right positioning to grow, prosper, lead and make a real difference in people’s lives,” added Steve Schuckenbrock, current CEO of Accretive Health, who accelerated his resignation from the position of CEO to be effective July 21, 2014 but will continue to assist with the transition through October 2, 2014, as well as continue to serve on the Company’s Board of Directors. “We have strengthened our operational execution over the last 15 months with a dedicated focus on our clients, invested more in technology than ever before, improved how we develop employees, and strengthened the company overall.”
“I want to thank Steve for the many contributions he has made to this Company. Since joining Accretive Health, he developed a strategy and set the Company on a course that will serve us well in the future. We sit on a stronger foundation because of Steve’s leadership, and I’m personally very happy that he will remain on the Board and be involved in this transition,” said Shulman. “Accretive Health will continue to pursue its vision to build a world-class revenue cycle management company that enhances our value proposition to our client partners through continuous innovation and a unique population health management strategy.”
About Accretive Health
At Accretive Health, our mission is to partner with healthcare communities to serve as a catalyst for a healthier future for all.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.